EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities

EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.

Story continues below

On February 14, 2010 the Company held initial closings and accepted subscriptions for $65,000 in a private placement offering of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing 2,600,000 shares of Common Stock. In addition, and through the date hereof, the Company has received additional subscriptions which bring the total subscriptions to $1,154,500 for a total of 46,180,000 shares of Common Stock. The offer and sale of these shares was made solely to “Accredited Investors” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”). We engaged in no general solicitation or advertising with regard to the offering. Accordingly, the offer and sale of these shares was exempt under Rule 506 of Regulation D under the Securities Act.

Following the issuance of common stock as described above, our total issued and outstanding common stock will be 165,133,712 shares.

SECTION 7 – REGULATION FD

Item 7.01 Regulation FD Disclosure

On February 21, we released the press release furnished herewith as Exhibit 99.1

Section 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description

Form of Subscription Agreement for Common Stock

Press Release

Exactus, Inc. Exhibit
EX-10.1 2 ex10-1.htm FORM OF SUBSCRIPTION AGREEMENT FOR COMMON STOCK Exhibit 10.1     Exhibit 10.1   SUBSCRIPTION AGREEMENT EXACTUS,…
To view the full exhibit click here

About EXACTUS, INC. (OTCMKTS:EXDI)

Exactus, Inc. (Exactus), formerly Spiral Energy Tech, Inc., is a life science company. The Company will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a detection platform. The Company’s primary business focus will be the development and commercialization of the FibriLyzer and related technology licensed by Exactus. The Company’s products will employ a disposable test biosensor strip combined with a portable hand held detection unit that provides a result in approximately 30 seconds. The Company intends to file to gain regulatory approval and launch its products in the United States and Europe.

An ad to help with our costs